





Trisomy 21 prevalence and socioeconomic status, in Victoria 2015-16

Eliza Kluckow¹, Jane Halliday^{1,2}, Alice Poulton¹, Anthea Lindquist^{1,3}, Lisa Hui^{1,3,4}, on behalf of the PeRL collaboration

Introduction

Background:

- Down Syndrome (also known as trisomy 21 or T21) is the most common chromosomal cause of intellectual disability in children
- This study was initiated in the context of low reported rates of T211, however a recent government report estimates T21 prevalence rate to be 3.0 per 1000 pregnancies²
- It is recommended that prenatal screening be offered to women irrespective of age and background
- Known barriers to being offered or accepting prenatal testing in Australia are younger age, non-English speaking, Indigenous or rural/ geographically isolated

Objectives:

- Provide up-to-date prevalence estimates of the common autosomal trisomies in Victoria
- Explore the association between timing of T21 diagnosis, maternal age and socioeconomic status (measured hv IRSAD quintile)

Methods

- diagnosis of trisomy T21 (T21), trisomy 18 (T18) or trisomy 13 (T13) in 2015-16 were included Datasets were obtained from the four cytogenetic
- laboratories in Victoria Prenatal dataset included diagnoses via
 - amniocentesis, chorionic villus sampling (CVS) or following termination of pregnancy (TOP) Postnatal dataset included diagnoses in live births and miscarriages/stillbirths
 - Screening dataset included combined first trimester screening, second trimester serum screening and non invasive prenatal testing
- Victorian birth numbers were obtained from The Consultative Council on Obstetric and Paediatric Mortality and Morbidity (CCOPMM) reports and the Australian Bureau of Statistics
- Record linkage was performed via LinkageWiz to identify duplicate prenatal and postnatal tests for the same pregnancy - these were assigned to prenatal group only
- Manual linkage was performed to match postnatally diagnosed T21 births with screening Socioeconomic status was assigned using Index of Relative Socio-economic Advantage and
- Disadvantage (IRSAD) from maternal postcode Chi² testing and logistic regression were performed in STATA v14

Results

- A total of 3662 prenatal and 6250 postnatal diagnostic tests were performed in Victoria during 2015-16
- There were 817 cases of the three common autosomal trisomies (517 prenatal and 300 postnatal diagnoses), giving a combined total prevalence of 5.0 /1000 births (Table 1)
- 17 pregnancies received both a prenatal and a postnatal diagnostic test for the same pregnancy
- infants, 67.4% during pregnancy and 19.8% following miscarriage/stillbirth


Among the T21 group, 12.8% were diagnosed in live

- Among the T18 and T13 cases, only 0.7% and 2.8% of diagnoses were made in live infants
- Of the women that had a T21 diagnosis, there was a significant association between timing of diagnosis and IRSAD quintile (x2 trend = 15.6, p = <0.01). The proportion of diagnoses in live newborns compared to prenatal diagnoses, decreased with increasing socioeconomic advantage (Fig 1)
- The live birth prevalence of T21 also decreased significantly with increasing socioeconomic advantage (Fig 2)
 - There were 73 postnatally diagnosed live T21 births. Of these, 76.7% did not utilise any prenatal screening and only 4.1% received a diagnostic confirmation prenatally
- Women aged 35+ made up 67.7% of women diagnosed with a T21 affected pregnancy

Table 1, Prevalence of T21, T18 and T13 in Victoria, 2015-2016

| | T21 | T18 | T13 | Total |
|---|------|------|------|-------|
| Total cases (no.) | 577 | 139 | 107 | 823 |
| Total prevalence / 1000 pregnancies ^a | 3.6 | 0.9 | 0.7 | 5.1 |
| Live births (no.) | 85 | 2 | 3 | 90 |
| Live births / 1000 live | 0.53 | 0.01 | 0.02 | 0.57 |

Fig 1. Prenatal T21 diagnosis versus newborn T21 diagnosis



- Denominator used to calculate rate per 1000 reported pregnancies (>20 weeks gestation) in Victoria in 2015-16 was 162 192³ (Table 1) Denominator used to calculate rate per 1000 live
- Ь. benominator used to Catculare late per 1000 five births in Victoria in 2015-16 was 158 870³ (Table 1) No. of newborn diagnosis / (no. of newborn diagnosis + no. of prenatal diagnosis) (Fig 1) No. of TZ1 live births / all live births, in Victoria, by
- d. quintile4 (Fig 2)

Fig 2. Rate of T21 live births per 1000 live births in Victoria by IRSAD quintile 1.2 1000 k ae of T21 live births 0.6 0.4 IRSAD quintile

Discussion/Conclusion

- These results highlight the importance of linking prenatal and postnatal cytogenetic datasets to:
 - accurately report prevalence 2) compare characteristics of women who receive a prenatal versus a postnatal diagnosis
 - gain an understanding of pathways through pregnancy The prevalence of T21 in Victoria was 3.5 per
- 1000 pregnancies, which is higher than previously reported1,2
- Only 12.8% of all diagnoses of T21 occur in live
- The majority of live T21 births were not screened prenatally and very few received prenatal diagnostic confirmation
- The significant association between socioeconomic disadvantage and having a live born infant with T21, raises important questions about access to, and utilization of, prenatal testing services
 - This association may have multiple causes, including patient factors (such as personal preference or attitudes toward prenatal testing), practitioner factors (such as lack of an offer of prenatal screening/diagnostic test) or external factors such as financial or geographical barriers to services

Acknowledgements

In addition to the named authors above, the members of the PeRL collaboration include the pathology laboratories of the PeRL collaboration include the pathology laboratories of the Victorian Clinical Genetics Service (Leonard Bonacquisto, Mark D Pertile), Monash Health (Lucy Gugasyan, Abhijit Kulkarni), Melbourne Pathology (Amanda Howden, James Harraway), Virtus Health (Nicole Martin), and Australian Clinical Labs (Richard McCoy); the private ultrasound practices of Women's Ultrasound Melbourne (Ricardo Palma-Disa, Debbie Nesbit), Monash Ultrasound for Women (Melody Menezes) and Specialist Women's Littrasound Michael Rebuson, and the Virtus la Infant Mercan's Ultrasound (Michael Bethune); and the Victorian Infant Hearing Screening Program (Zeffie Poulakis)

References

I. Victorian Congenital Anomalies Register: Congenital Anomalies in Victoria 2014. Melbourne: Consultative Council on Obstetric and Paediatric Mortality and Morbidity (COPMM); 2017

2. Victorian Congenital Anomalies Register: Congenital Anomalies in Victoria 2015-16. Melbourne: The Consultative Council on Obstetric ar Paediatric Mortality and Morbidity (COPMM); 2017

3. Department of Heatth & Human Services State Government of Victoria. Victoria's Mothers Bables and Children Report 2015-16. Melbourne: Consultative Council on Obstetric and Paediatric Mortality and Morbidity (COPPM); 2017

4. Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), IRSAD (Accessed 1 March 2018). Available from URL http://www.abs.gov.au/ausstats

Affiliations

- Public Health Genetics, Murdoch Children's Research Institute
- ent of Paediatrics, University of Melbourne, Parkville VIC
- elercy Perinatal, Mercy Hospital for Women, Melbourne, Australia department of Obstetrics and Gynaecology, University of Melbourne